Fosamax alendronate sodium data

MRK (West Point, Penn.) is to present on June 14 results in 994 women, showing progressive increase in bone mineral density at the spine and hip, and reduced incidence of new vertebral fractures. The company will report at the meeting of the Endocrine Society that the non-hormonal agent reduced new fractures by 48 percent compared to placebo.

The most effective dose was 10 mg daily. After three years of this dosage, bone mineral density was increased at the spine and hip by 8.2 and 7.2 percent respectively, while patients on placebo lost 0.7 percent of bone density at each site. ...